Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

below a Forbes article on how Durata was thinking about pitching Dalvance... which again didn't have anywhere close to the efficacy of Brilacidin, not a single-dose (at the time), and was "trialed" against a weaker comparator (Vanco)

http://www.forbes.com/sites/wendydiller/2014/06/05/how-durata-plans-to-market-its-expensive-new-antibiotic/

here is PR on dalvance's recent single-dose trial (primary endpoints still not as strong as B)
http://www.prnewswire.com/news-releases/actavis-announces-topline-phase-3-clinical-trial-results-for-single-dose-dalvance-dalbavancin-in-the-treatment-of-absssi-300071751.html

links to the recent ABSSSI approvals for those who might be interested in followup to Biodoc's topline summary

Dalvance / May 2014
http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/1329/dalvance-dalbavancin

Sivextro / June 2014
http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/100013/sivextro-tedizolid-phosphate-

Orbactiv / August 2014
http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/100025/orbactiv-oritavancin

last, another take on Symbiomix "A New Old Antibiotic"
http://pipeline.corante.com/archives/2015/05/06/a_new_old_antibiotic.php